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Abstract
Glypican 3 (GPC3) is a valuable diagnostic marker and a potential therapeutic target in hepatocellular carcinoma
(HCC). To evaluate the efficacy of targeting GPC3 at the translational level, we used RNA interference to examine
the biologic and molecular effects of GPC3 suppression in HCC cells in vitro and in vivo. Transfection of Huh7 and
HepG2 cells with GPC3-specific small interfering RNA (siRNA) inhibited cell proliferation (P < .001) together with
cell cycle arrest at the G1 phase, down-regulation of antiapoptotic protein (Bcl-2, Bcl-xL, and Mcl-1), and replicative
senescence. Gene expression analysis revealed that GPC3 suppression significantly correlated with transforming
growth factor beta receptor (TGFBR) pathway (P= 4.57e−5) and upregulated TGF-β2 at both RNA and protein levels.
The effects of GPC3 suppression by siRNA can be recapitulated by addition of human recombinant TGF-β2 to HCC
cells in culture, suggesting the possible involvement of TGF-β2 in growth inhibition of HCC cells. Cotransfection of
siRNA-GPC3 with siRNA–TGF-β2 partially attenuated the effects of GPC3 suppression on cell proliferation, cell cycle
progression, apoptosis, and replicative senescence, confirming the involvement of TGF-β2 in siRNA-GPC3–mediated
growth suppression. In vivo, GPC3 suppression significantly inhibited the growth of orthotopic xenografts of Huh7
and HepG2 cells (P < .05), accompanied by increased TGF-β2 expression, reduced cell proliferation (observed by
proliferating cell nuclear antigen staining), and enhanced apoptosis (by TUNEL staining). In conclusion, molecular
targeting of GPC3 at the translational level offers an effective option for the clinical management of GPC3-positive
HCC patients.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer
worldwide and the third most common cause of cancer mortality [1].
It is typically aggressive and intrinsically resistant to standard chemo-
therapeutic agents, underscoring the need for developing more effec-
tive therapies for HCC patients [2,3]. Recent studies have implicated
glypican 3 (GPC3) as an important protein in HCC. As a histologic
marker, GPC3 staining could distinguish malignant HCC from pre-
neoplastic, cirrhotic, or benign liver lesions [4–9]. As a serum marker,
the cleaved and secreted form of GPC3 was found to be elevated in the
serum of HCC patients, making it a valuable, noninvasive diagnostic
marker of HCC [10–12]. Functionally, GPC3 promotes growth of
HCC cells through stimulation of the canonical Wnt signaling pathway
[13], which regulates the expression of many downstream oncogenic
proteins such as c-MYC [14]. Given the importance of Wnt signaling
in HCC [15], GPC3 may also have therapeutic potential in the clinical
management of HCC.
GPC3 was first identified in patients with Simpson-Golabi-Behmel
syndrome, an X-linked disease characterized by prenatal and postnatal
overgrowth caused by mutation of the GPC3 gene [16]. It is one of six
members of the glypican family, which are heparan sulfate proteoglycans
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that are linked to the exocytoplasmic surface of the plasma membrane
by a glycosyl-phosphatidylinositol (GPI) anchor [17]. Glypicans play a
critical role in the regulation of cell proliferation and survival, particularly
during development and malignant transformation [18–21]. The main
function of membrane-attached glypicans is to regulate the signaling of
Wnts, Hedgehogs (Hhs), fibroblast growth factors, and bone morpho-
genic proteins (BMPs) [20,22–24]. Depending on the cellular context,
glypicans may have a stimulatory or inhibitory role in these signaling
pathways: in tissues where cell proliferation is predominantly controlled
by Hh signaling, GPC3 overexpression inhibits proliferation, whereas
in tissues where canonical Wnt signaling predominates, GPC3 over-
expression stimulates cell proliferation [25].
In HCC, GPC3 interacts with Wnt ligands acting in the canonical
pathway to stimulate cell proliferation [15]. Cellular proliferation in-
duced by Wnt3a has recently been attributed to activation of both the
extracellular signal–regulated kinase (ERK) andWnt pathways [26], both
of which are implicated in hepatocarcinogenesis associated with hepatitis
B or C virus infections, the major risk factors of HCC [27]. In addition,
GPC3 has been reported to confer hepatocarcinogenesis through the in-
teraction between insulin-like growth factor II and its receptor, with sub-
sequent activation of the insulin growth factor signaling pathway [28].
The interaction between GPC3 and fibroblast growth factor basic has
also been reported to modulate proliferation of HCC cells [23] and
could, in part, mediate the oncogenic effect of sulfatase 2 in HCC
[29]. Indeed, the overexpression of GPC3 in HCC patients has been
positively correlated with fibroblast growth factor receptor 1, insulin-like
growth factor 1 receptor, and nuclear localization of β-catenin [30].
The elevated expression of GPC3 in HCC and its potential in-
volvement inmultiple signaling pathways contributing to hepatocarcino-
genesis together suggest that inhibition of GPC3 may offer a potent and
molecularly targeted strategy for intervening with HCC progression. In
this study, we confirmed that suppression of GPC3 in HCC cells by
RNA interference led to inhibitory effects on cell growth and cell cycle
progression. We additionally provide further mechanistic insights into
another signaling pathway, the transforming growth factor β (TGF-β)
pathway, which might be involved in GPC3-mediated functions in
HCC. Taken together, our data provide support that molecular target-
ing of GPC3 at the translational level is an effective treatment strategy
for HCC, which has heterogeneous pathology.
Materials and Methods
Cell Culture
The human HCC cell lines Huh7 and HepG2 were cultured in
Dulbecco modified Eagle medium and minimum essential medium,
respectively (Gibco/Invitrogen, Carlsbad, CA). Media were supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and
100 μg/ml streptomycin (Invitrogen). Cells were cultured at 37°C in a
humidified atmosphere of 5% CO2.
Small Interfering RNA Transfection In Vitro
GPC3-specific small interfering RNA (siRNA-GPC3), TGF-β2–specific
siRNA (siRNA-TGFβ2), and silencer-negative control siRNA (siRNA-N)
were purchased from Ambion, Inc (Austin, TX). Sequences for GPC3
and TGF-β2–specific siRNAs used for the experiments were as follows:
siRNA-GPC3: (GGCUCUGAAUCUUGGAAUUtt), s14750
siRNA–TGF-β2: (CACUCGAUAUGGACCAGUUtt), s14059
The transfection reagent Lipofectamine RNAiMAX (Invitrogen) was
used to transfect siRNA oligos into Huh7 and HepG2 cells, using the
reverse transfectionmethod according to themanufacturer’s instructions.
Cell Proliferation Assay
Huh7 andHepG2 cells reverse transfectedwith siRNA-GPC3 (25nM)
or siRNA-N (25 nM) were seeded onto 96-well plates in triplicate wells
(4000 cells/well) in culture medium without antibiotics. At the indi-
cated time points, cell viability was determined by the CellTiter 96
AQueous One Solution Cell Proliferation Assay (Promega, Madison,
WI) according to the manufacturer’s protocol. Optical density (OD)
was read at 490 nm using a microplate reader (BioTek Instruments,
Inc, Winooski, VT). Once cells have attached (approximately 4 hours
after transfection), an OD value was obtained as the first time point.
The background values (OD values from wells with only the AQueous
One Solution) were subtracted from all data. Three independent ex-
periments were done. For experiments with recombinant human (rh)
TGF-β2 (R&D Systems, Minneapolis, MN), 1 or 5 ng/ml of TGF-β2
was added to the culture medium, and the effects on proliferation of
Huh7 and HepG2 cells were determined as described previously.
Cell Cycle Analysis by Flow Cytometry
Huh7 and HepG2 cells were synchronized at the G0/G1 phase by
culturing in serum-free medium for 24 hours, then transfected with
siRNA-N, siRNA-GPC3 alone, or siRNA-GPC3 with siRNA–TGF-
β2 for 48 hours. Cells were then stimulated with 20% FBS for 24 hours
and trypsinized, washed, and fixed in 70% ethanol for 30 minutes
at 4°C. Fixed cells were stained with propidium iodide with RNaseA
in 1× PBS for data acquisition using BD LSRII flow cytometer (BD
BioSciences, Franklin Lakes, NJ). Data were analyzed by using FlowJo
version 7.5.5 (Tree Star, Ashland, OR). Three independent experi-
ments were done for each experiment set.
Protein Extraction and Western Blot Analysis
Transfected cells were harvested and lysed in T-PER Tissue Protein
Extraction Reagent (Thermo Scientific, Inc, Waltham, MA) for isola-
tion of total cell lysates. For the isolation of nuclear and cytoplasmic
fractions, NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Scientific) were used according to the manufacturer’s instruc-
tions. Western blot analysis was performed using standard protocols
with specific antibodies against the antigens according to the manu-
facturer’s recommendations. Monoclonal antibody against human
GPC3 (clone 1G12) was fromBioMosaics, Inc (Burlington, VT); mono-
clonal antibody against TGF-β2 and Histone H3 were from AbCam
(Cambridge, MA); polyclonal antibodies against PCNA and β-actin
were from Santa Cruz Biotechnology (Santa Cruz, CA); and mono-
clonal antibody against cyclin D1 was from Thermo Scientific. All
other antibodies were purchased from Cell Signaling Technology, Inc
(Danvers, MA).
Oligonucleotide Microarray Analysis
Genome-wide expression analysis was done using the Agilent 60-mer
Oligonucleotide Two-Color Microarray System (Agilent Technologies,
Inc, Santa Clara, CA). Total RNA was extracted from siRNA-N– or
siRNA-GPC3–treated cells by using RNeasy mini kit (Qiagen, Valencia,
CA). The integrity of the RNA was confirmed by the Agilent 2100
Bioanalyzer (Agilent Technologies). RNA samples with RIN num-
ber 8 or higher were used for further experiments. The RNA samples
were amplified and labeled using the Agilent Quick Amp labeling kit
736 GPC3 Suppression Inhibits HCC Growth via TGF-β2 Sun et al. Neoplasia Vol. 13, No. 8, 2011
according to the manufacturer’s instructions. After fragmentation,
1650 ng of complementary RNA was hybridized onto a 4 × 44K oligo-
nucleotide array at 65°C for 17 hours. The array was then washed and
scanned using GenePix 4000A scanner (Agilent Technologies). Data
were extracted by using Feature Extraction software and uploaded onto
the Stanford Microarray Database (SMD; http://smd.stanford.edu).
Supervised analysis using Significance Analysis of Microarrays was used
to identify genes that are significantly differentially expressed between
siRNA-GPC3–treated cells and siRNA-N–treated cells (a two-fold
change cutoff was used). Significantly, differentially regulated pathways
were identified using GeneSpring GX11 (Agilent Technologies).
Semiquantitative Real-time Polymerase Chain Reaction
Total RNA was extracted using RNeasy Mini kit (Qiagen) and
reverse transcribed using TaqMan Reverse Transcription Reagent
(Applied Biosystems, Foster City, CA). Semiquantitative real-time
polymerase chain reaction (PCR) was carried out, and data were
analyzed using a MX3000P Real-time PCR machine (Stratagene,
La Jolla, CA). Primers and probe reagents for human GPC3 (assay
no. Hs00170471_m1), TGF-β1 (assay no. Hs00998129_m1), TGF-β2
(assay no. Hs00234244_m1), TGF-β3 (assay no. Hs01086000_m1),
and 18S rRNA (normalization control; assay no. 4333760F) were
purchased as Pre-Developed TaqMan Gene Expression Assay reagents
from Applied Biosystems. Transcript quantification was performed in
at least duplicate for every sample. The amount of each target gene was
normalized with 18S rRNA to control for RNA amount variation.
Senescence-Associated β-Gal Staining
Senescence β-galactosidase (SA-β-Gal) staining was performed by
using the staining kit according to the manufacturer’s instructions
(Cell Signaling Technology, Inc, Danvers, MA). Briefly, cells were
transfected with siRNA-GPC3 or incubated with rhTGF-β2 (1 or
5 ng/ml) for 48 hours before fixing and staining. After SA-β-Gal
staining, cells were counterstained with Nuclear Fast Red Solution
(Electron Microscopy Sciences, Hatfield, PA), and images were ac-
quired using a fluorescence microscope (Nikon, Melville, NY).
Lentiviral Labeling of Cell Lines and Cell Sorting
Huh7 and HepG2 cells were transduced with self-inactivating len-
tivirus carrying an ubiquitin promoter driving a trifusion reporter
gene, which harbors a bioluminescence (firefly luciferase [Fluc]), a
fluorescence (mrfp or egfp), and a positron emission tomography re-
porter gene (ttk) at a multiplicity of infection of 5 as reported previ-
ously [31]. Stable expressors were isolated by sorting at 45 pound-force
per square inch (BD FACS Aria II; BD BioSciences).
Animal Studies
Animal experiments were approved by the Administrative Panel
on Laboratory Animal Care of Stanford University. Orthotopic liver
tumor models of Huh7 and HepG2 cells (stably expressing the tri-
fusion reporter gene) were established in nude mice as reported previ-
ously with some modifications [32]. Briefly, ∼1 × 107 cells in 200 μl of
culture mediumwere injected subcutaneously into the right flank of nu/
nu nude mice (4 weeks old; Charles River Laboratories, Wilmington,
MA). Tumor development was monitored daily. Once the subcuta-
neous tumor reached 1 cm in diameter, it was removed and cut into
∼1- to 2-mm3 cubes, which were then surgically implanted into the
left lobe of liver in another group of nude mice (6 weeks old). The mice
were given intraperitoneal injections of 25 nM siRNA-GPC3 in 100 μl
of PBS or siRNA-N as control (five mice each) every 3 days. Tumor
growth was monitored once a week for 7 weeks using the Xenogen IVIS
in vivo imaging system (Caliper Life Sciences,Hopkinton, CA).Growth
curves were plotted using average bioluminescence within each group.
Immunohistochemistry for Cell Proliferation and Apoptosis
Immunostaining was performed as reported previously [32]. Briefly,
paraffin slides were stained with anti–proliferating cell nuclear antigen
(PCNA; Santa Cruz Biotechnology) or anti–TGF-β2 monoclonal
antibody (AbCam) at 4°C overnight followed by the avidin-biotin-
peroxidase protocol. Terminal deoxynucleotidyl transferase biotin–
dUTP nick end labeling (TUNEL) assay was done according to the
manufacturer’s protocol (Roche Applied Science, Indianapolis, IN).
Statistical Analysis
The statistical analyses were done using the SPSS version 15.0 soft-
ware package (SPSS, Inc, Chicago, IL). Statistical significance was
determined by independent-samples t test. P < .05 and P < .01 were
considered statistically significant and highly significant, respectively.
Results
Suppression of GPC3 Inhibits In Vitro Proliferation and
Cell Cycle Progression in Huh7 and HepG2 Cells
We transfected two tumorigenic hepatoma cell lines (Huh7 and
HepG2) that overexpress GPC3 protein (based on Western blot re-
sults) with 25 nM of a GPC3-specific siRNA (siRNA-GPC3) and ob-
served greatly reduced expression of glycanated and core GPC3 protein
in both cell lines compared with cells transfected with vehicle control
or with silencer-negative siRNA (siRNA-N; Figure 1A). Transfection
with siRNA-GPC3 also reduced proliferation of Huh7 cells (P < .001
from 72 hours) and HepG2 cells (P < .001 from 48 hours) when
assessed daily during a 5-day period (Figure 1B).
To determine whether the growth-inhibitory effects of GPC3 sup-
pression could result from changes in the cell cycle, we measured
cellular DNA content by flow cytometry after cell synchronization by
serum starvation, followed by transfection with siRNA-GPC3 for
48 hours and restimulation with 10% FBS for 24 hours. Suppression
of GPC3 caused a significant increase in G1 peak in HepG2 cells (P =
.04 compared with siRNA-N), together with a decrease in S-phase cells
(P = .039; Figure 1C ). The expression of cell cycle regulators, cyclin A
and cyclin D1, were also downregulated by siRNA-GPC3 in HepG2
cells (Figure 1C). These changes in the cell cycle were less obvious in
the Huh7 cells, which showed a small increase in the G0/G1 peak (P =
.31 compared with siRNA-N) but an insignificant change in the S
peaks (P = .90; Figure 1D). In Huh7 cells, the levels of cyclin A and
cyclin D1 were also reduced to a lesser extent than in HepG2 cells
(Figure 1D). Thus, the effect of GPC3 suppression on cell growth
and cell cycle progression is more marked in HepG2 cells, which have
higher levels of GPC3 than Huh7 cells.
Identification of TGF-β2 as an Important Modulator of
GPC3-Mediated Signaling
To characterize the signaling pathways and molecular changes regu-
lated by GPC3 in HCC cells, we studied the gene expression changes in-
duced by siRNA-GPC3 compared with their siRNA-N–transfected
controls. Pathway analysis usingGeneSpringGX 11 identified five signaling
pathways that are significantly regulated by GPC3 suppression: nuclear
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Figure 1. Suppression of GPC3 by siRNA-GPC3 inhibits in vitro cell proliferation and cell cycle progression of Huh7 and HepG2 cells.
(A) Transfection of GPC3-specific siRNA (siRNA-GPC3) efficiently suppressed expression of core and glycanated forms of GPC3 protein
in Huh7 and HepG2 cells. (B) Growth rates of siRNA-GPC3–transfected and control cells were determined using the proliferation assay
described under Materials and Methods. Data were obtained from three independent experiments, with triplicates in each experiment.
(C, D) Cell cycle analysis by flow cytometry showed that siRNA-GPC3 caused significant cell cycle arrest at the G1 phase in HepG2 cells
(C) but only an insignificant change in Huh7 cells (D). Western blots with antibodies against cyclin A and cyclin D1 support these observa-
tions. Only P values for comparing G1 cell populations are shown. siRNA-G indicates cells transfected with siRNA-GPC3; siRNA-N, cells
transfected with siRNA-N; V, vehicle control. Number of independent experiments = 3.
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factor κB (P = 3.73e−6), TGFBR (P = 4.57e−5), EGFR1 (P = 1.43e−4),
IL-6 (P = 6.43e−4), and Wnt (P = .008). Using Significance Analysis of
Microarrays, biologically relevant genes that are commonly, significantly
upregulated or downregulated in both HepG2 and Huh7 cell lines were
identified using a two-fold change cutoff and P < .0001 (Table 1 and
Figure 2A). Biologic functions of encoded proteins were compiled from
the SOURCE database available at the SMD. Amember of the TGFBR
pathway, TGF-β2 (but not TGF-β1 or TGF-β3), was significantly
upregulated by GPC3 suppression in both Huh7 and HepG2 cells
(P < .05, siRNA-N vs siRNA-GPC3; Figure 2B). The up-regulation
of TGF-β2 by siRNA-GPC3 was independently validated using
semiquantitative RT-PCR (Figure 2B) and Western blot analysis
(Figure 2C) to confirm the negative correlation at both transcript and
protein levels, respectively. Two additional GPC3-specific siRNAs
(GGGAACCACUUUCUUAUUUtt; GACGUGACCUGAAAGUA-
UUtt) were used to verify this observation (data not shown). Further
analysis of GPC3 and TGF-β2 protein expression in a panel of nine
HCC cell lines confirmed this negative correlation: cell lines expressing
GPC3 have lower levels of TGF-β2, whereas cell lines with undetectable
GPC3 have higher levels of TGF-β2 (Figure 2D). Our results suggest a
close association between GPC3 and TGF-β2 in the TGFBR signaling
pathway.
TGF-β2 Suppresses Cell Proliferation by Activating R-SMADs
in Huh7 and HepG2 Cells
To determine whether the growth-inhibitory effects of GPC3 sup-
pression might be partially mediated by TGF-β2, we next looked at
the effects of rhTGF-β2 on HCC cell proliferation. Cells were cul-
tured with or without rhTGF-β2 and cell growth was assessed daily
for 5 days. We found that rhTGF-β2 significantly inhibited cell pro-
liferation in both Huh7 and HepG2 cells (P < .01 for both cell lines;
Figure 3A). Important components of the TGF-β pathway, SMAD2
and SMAD3, were hyperphosphorylated on addition of rhTGF-β2
together with nuclear translocation of SMAD 6 (Figure 3B). Our re-
sults imply that TGF-β2 negatively regulates HCC cell proliferation
through the activation of R-SMADs, allowing transduction of extra-
cellular TGF-β2 superfamily ligand signaling from cell membrane–
bound TGF-β receptors into the nucleus where they activate the
transcription of TGF-β target genes.
TGF-β2 Suppresses Cell Cycle Progression and Induces
Replicative Senescence in Huh7 and HepG2 Cells
To determine whether the cell cycle effects of GPC3 suppression
might be partially mediated by TGF-β2, we looked at the effect of
rhTGF-β2 on cell cycle progression of HCC cells. Huh7 and HepG2
cells were grown in culture medium supplemented with rhTGF-β2
(1 or 5 ng/ml) for a period of 48 hours before flow cytometry analy-
ses. Similar to the effects of GPC3 suppression (Figure 1C ), sig-
nificant increases in the G1 peak (P = .016 for Huh7 cells and P <
.001 for HepG2 cells), together with a decrease in S- and G2-phase
cells were observed in both cell lines compared with control cells not
treated with rhTGF-β2 (P < .001 and P = .034 for S and G2 phases,
respectively, for HepG2 cells; P = .017 and P = .004 for S and G2
phases, respectively, for Huh7 cells) (Figure 4A). Western blot analy-
sis further showed that rhTGF-β2 decreased the expression of cell
cycle regulators cyclin A and cyclin D1 (Figure 4B), as observed with
GPC3 suppression (Figure 1C ). In addition, phosphorylation of
retinoblastoma (Rb) protein was decreased, whereas the expression
of p15Ink4b and p21Cip1 were increased in both Huh7 and HepG2
cells, indicating a G1 cell cycle arrest (Figure 4B). The addition of
TGF-β2 also increased the apoptotic response, demonstrated by the
reduced expression of antiapoptotic proteins (Bcl-xL and Mcl-1) in
both cell lines, and the reduced expression of Bcl-2 in HepG2 cells only
(Huh7 cells do not express Bcl-2) (Figure 4B).
Consistent with a recent report that TGF-β1 induces p15Ink4b- and
p21Cip1-dependent senescence in HCC cells [33], we also observed
that addition of rhTGF-β2 induced cellular senescence in both Huh7
and HepG2 cells as shown by enhanced accumulation of SA-β-Gal
(Figure 4C). Taken together, these results suggest that TGF-β2 nega-
tively mediates cell cycle progression through modulation of various
Table 1. Genes Commonly Significantly Upregulated or Downregulated by GPC3 Suppression in HepG2 and Huh7 Cells.
Gene Symbol Gene Name Biologic Function of Encoded Protein Fold Change (HepG2) Fold Change (Huh7)
NUDT15 Nudix (nucleoside diphosphate linked
moiety X)-type motif 15
May have a role in DNA synthesis and cell cycle progression through interaction
with PCNA.
31.34 2.18
HIPK3 Homeodomain interacting protein kinase 3 Androgen receptor–interacting nuclear protein kinase, to negatively regulate
apoptosis by promoting FADD phosphorylation; enhances androgen
receptor–mediated transcription.
16.45 2.65
TGFB2 Transforming growth factor, beta 2 Member of the transforming growth factor beta (TGFB) family of cytokines,
which are multifunctional peptides that regulate proliferation, differentiation,
adhesion, migration, and other functions in many cell types.
10.37 3.61
XPR1 Xenotropic and polytropic retrovirus receptor Expressed in fetal liver; may function in G protein–coupled signal transduction. 6.59 2.77
PANK3 Pantothenate kinase 3 Key regulatory enzyme in the biosynthesis of coenzyme A (CoA) in bacteria and
mammalian cells; expressed most abundantly in the liver.
4.86 2.27
GDF11 Growth differentiation factor 11 Member of the bone morphogenetic protein (BMP) family and the TGF-beta
superfamily. Members of this family are regulators of cell growth and
differentiation in both embryonic and adult tissues.
3.52 2.15
TOP1MT Topoisomerase (DNA) I, mitochondrial Enzyme that controls and alters the topologic states of DNA during transcription;
highly expressed in fetal liver.
3.15 2.18
GPC3 Glypican 3 Member of the glypican-related integral membrane proteoglycan family (GRIPS);
may play a role in the control of cell division, growth regulation, and tumor
predisposition.
0.11 0.14
RORA Retinoic acid receptor–related orphan
receptor A
Member of the NR1 subfamily of nuclear hormone receptors; enhances expression
of hormone response genes. Shown to interact with NM23-2, a nucleoside
diphosphate kinase involved in organogenesis and differentiation, as well as with
NM23-1, the product of a tumor metastasis suppressor candidate gene.
0.28 0.48
Fold change is expressed as the ratio of mean abundance of transcript in siRNA-GPC3–treated cells compared with siRNA-N– (negative control) treated cells.
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Figure 2. Identification of TGF-β2 as an important mediator in GPC3 signaling by oligonucleotide microarray analysis. (A) Heat map
showing nine significantly upregulated or downregulated genes associated with GPC3 suppression in both Huh7 and HepG2 cells. Rows
represent individual genes and columns represent individual cell sample. In each sample, the log2 ratio of abundance of transcripts of each
gene relative to its mean abundance across all samples is depicted according to the color scale shown at the bottom left. (B) Transfection
of Huh7 and HepG2 cells with siRNA-GPC3 upregulated TGF-β2 but not TGF-β1 or TGF-β3 at the transcriptional level as measured by
quantitative PCR. Fold difference indicates the ratio of relative RNA quantity (siRNA-GPC3/siRNA-N); *P < .05. Number of independent
experiments = 3. (C) Validation of increased protein expression of TGF-β2 in both cell lines transfected with siRNA-GPC3. (D) Protein
expression levels of GPC3 and TGF-β2 in a panel of HCC cell lines as detected byWestern blot analysis. siRNA-G indicates cells transfected
with siRNA-GPC3; siRNA-N, cells transfected with siRNA-N; V, vehicle control.
740 GPC3 Suppression Inhibits HCC Growth via TGF-β2 Sun et al. Neoplasia Vol. 13, No. 8, 2011
cell cycle regulators, thereby contributing to G1 arrest, apoptosis,
and senescence.
TGF-β2 siRNA Partially Reverses Growth Inhibition,
Cell Cycle Arrest, and Replicative Senescence Caused
by siRNA-GPC3
We next cotransfected siRNA–TGF-β2 with siRNA-GPC3 in HCC
cells to interfere with the rise in TGF-β2 levels caused by siRNA-
GPC3 alone and to observe the resulting effects on cell proliferation
and cell cycle progression. The cotransfection of siRNA–TGF-β2 with
siRNA-GPC3 partially reversed the growth-inhibitory effects of GPC3
suppression in HepG2 cells but had negligible effect in Huh7 cells
(Figure 5A). When the increase in TGF-β2 levels was reduced by
siRNA–TGF-β2, cells proliferated faster than when treated with siRNA-
GPC3 alone. These effects of cell proliferation were also reflected by the
levels of SMAD2 and SMAD3 phosphorylation: siRNA-GPC3 alone
caused an increase in SMAD2 and SMAD3 phosphorylation in both
Huh7 and HepG2 cells; this increase was partially attenuated when cells
were cotransfected with siRNA–TGF-β2 (Figure 5B). Thus, TGF-β2
may partially mediate the effect of GPC3 on HCC cell proliferation.
Cell cycle arrest at the G1 phase caused by siRNA-GPC3 was partially
reversed when cells were cotransfected with siRNA–TGF-β2. In HepG2
cells, cotransfection with siRNA–TGF-β2 decreased the G1 peak when
compared with siRNA-GPC3–treated controls; a similar but less pro-
nounced effect was observed in Huh7 cells (Figure 6A). Cotransfection
with siRNA–TGF-β2 also negated the decrease in cyclin A and cyclin
D1 levels caused by GPC3 siRNA in HepG2 cells (Figure 6B). In ad-
dition, cotransfection with TGF-β2 siRNA decreased the levels of
p15Ink4b and p21Cip1 while increasing the levels of antiapoptotic pro-
teins Bcl-2, Bcl-xL, and Mcl-1 that were regulated by siRNA-GPC3 in
HepG2 cells (Figure 6B). In Huh7 cells, cotransfection with siRNA–
TGF-β2 caused little effect on the levels of cyclin A, cyclin D1, p15Ink4b,
or p21Cip1 but instead increased the phosphorylation of Rb and the levels
of Bcl-xL and Mcl-1 that were reduced by siRNA-GPC3 (Figure 6B).
Transfection with siRNA-GPC3 alone caused marked accumulations
of SA-β-Gal in both cell lines, which were significantly reduced when
both cell lines were cotransfected with siRNA–TGF-β2 (Figure 6C ).
These results showed that cotransfection with siRNA–TGF-β2 can par-
tially reverse the cell cycle arrest and replicative senescence induced by
GPC3 suppression, implying that TGF-β2 may partially mediate the
effects of GPC3 on regulation of cell cycle and senescence.
Suppression of GPC3 Delays HCC Xenograft Growth and
Upregulates Cytoplasmic TGF-β2 In Vivo
Finally, we generated orthotopic tumors of Huh7 and HepG2 cells
in nude mice to confirm the growth-inhibitory effects of siRNA-GPC3
Figure 3. Human recombinant TGF-β2 inhibits cell proliferation and activates R-SMAD in HepG2 and Huh7 cells. (A) TGF-β2 suppressed
proliferation of HCC cells as shown by cell proliferation assay. Cells were cultured in media with different concentrations of rhTGF-β2 (1
or 5 ng/ml) as described in Materials and Methods. Data were obtained from three independent experiments, with triplicates in each
experiment. (B) Effects of TGF-β2 on phosphorylation of R-SMAD2/3 and nuclear translocation of SMAD6 as shown by Western blot
analysis. Histone H3 was used as the loading control for nuclear proteins. Number of independent experiments = 3.
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in vivo. Tumor-bearing mice were given intraperitoneal injections of
25 nM siRNA-GPC3 (n = 5) or siRNA-N (n = 5) in 100 μl of PBS
every 3 days until the tumors reached the criteria for euthanasia. Tumor
growth was monitored by noninvasive in vivo luciferase imaging. In the
HepG2 group, all mice treated with siRNA-GPC3 had a significantly
smaller tumor size compared with that observed in mice treated with
siRNA-N (P < .05 fromweek 3 onward) (Figure 7A). In theHuh7 group,
mice treated with siRNA-GPC3 had smaller tumor volume when com-
pared with mice treated with siRNA-N, although statistical significance
was not reached (P> .05; Figure 7B). Concomitantly, tumors treatedwith
Figure 4. Human recombinant TGF-β2 inhibits cell cycle progression and induces replicative senescence in HCC cells. (A) Addition of
rhTGF-β2 to the culture media inhibited cell cycle progression through G1 arrest in both HepG2 and Huh7 cells. Only P values for comparing
G1 cell populations are shown. (B) Addition of rhTGF-β2 to culture media caused changes in the expression of cell cycle regulators and
antiapoptotic proteins as detected by Western blot analysis. (C) Addition of rhTGF-β2 to culture media also induced accumulation of
SA-β-Gal staining in Huh7 and HepG2 cells, indicative of replicative senescence. *P < .05 versus vehicle control group. Number of inde-
pendent experiments = 3.
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siRNA-GPC3 had markedly lower expression of GPC3 but enhanced
expression of cytoplasmic TGF-β2 in the tumor cells (Figure 7C ). In
addition, we determined the effects of GPC3 suppression on cell pro-
liferation by PCNA immunohistochemistry and on apoptosis by the
TUNEL assay (Figure 7C). The siRNA-GPC3–treated tumors expressed
reduced levels of PCNA and contained more apoptotic nuclei in both
Huh7 and HepG2 xenografts, suggesting that GPC3 suppression in-
hibited xenograft growth by reducing cell proliferation while inducing
apoptosis in vivo. These effects positively correlated with up-regulation
of TGF-β2.
Discussion
Our previous gene expression study of human HCC identified
GPC3 as the most highly overexpressed membrane-bound protein
in HCC compared with nontumor liver and the second most highly
overexpressed secretory protein (after AFP) [34]. Until lately, much
of the focus on GPC3 has been on its diagnostic potential. In this
study, we validated the therapeutic potential of GPC3 in HCC and
reported the involvement of TGF-β2 in GPC3-mediated signaling
in HCC cells. Specifically, we showed that suppression of GPC3
in HCC cells enhanced TGF-β2 expression and signaling, which
inhibited cell proliferation and cell cycle progression, and induced rep-
licative senescence.
GPC3 is a rational target for the treatment of HCC because it is
predominantly expressed in HCC tumors compared with its adjacent
nontumor or cirrhotic tissues [5], implying specificity. In addition, it
potentially regulates multiple pathways involved in hepatocarginogensis
[20,22–24], implying a broad spectrum of activity. Several recent stud-
ies have investigated different approaches of targeting GPC3, such as
the use of anti-GPC3 monoclonal antibody [35] and HLA-A2– and
-A24–restricted GPC3-derived peptide for the immunotherapy for
HCC [36]. These approaches are based on the induction of antibody-
dependent cellular cytotoxicity and/or complement-dependent cyto-
toxicity and on the peptide induction of cytotoxic T lymphocytes,
respectively, which, in turn, reduced HCC tumor mass. A mutated,
soluble form of GPC3 was also reported to inhibit Wnt signaling in
HCC cells, leading to antitumor effects [37]. Our study demonstrates
Figure 5. Transfection of siRNA–TGF-β2 partially reverses the growth inhibition caused by GPC3 suppression. (A) Cotransfection of
siRNA–TGF-β2 with siRNA-GPC3 partially reversed the growth inhibition caused by siRNA-GPC3 alone in HepG2 cells, with negligible
effect in Huh7 cells. (B) Cotransfection of siRNA–TGF-β2 siRNA with siRNA-GPC3 partially downregulated the activation of SMAD sig-
naling pathway resulting from GPC3 suppression. siRNA G + T indicates cells cotransfected with siRNA-GPC3 and siRNA–TGF-β2;
siRNA-G, cells transfected with siRNA-GPC3; siRNA-N, cells transfected with silencer negative control siRNA; siRNA-T, cells transfected
with siRNA–TGF-β2.
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Figure 6. Transfection of siRNA–TGF-β2 partially reverses the cell cycle arrest caused by GPC3 suppression. (A) Cell cycle analysis by
flow cytometry indicated that siRNA–TGF-β2 partially reversed the G1 arrest induced by GPC3 suppression in HepG2 cells and, to a lesser
extent, in Huh7 cells. (B) Cotransfection of siRNA–TGF-β2 with siRNA-GPC3 correspondingly showed partial reversal of expression levels
of cell cycle regulators and antiapoptotic proteins induced by siRNA-GPC3 alone. (C) Cotransfection of siRNA–TGF-β2 and siRNA-GPC3
also partially reduced the accumulation of SA-β-Gal caused by GPC3 suppression. siRNA-G + T indicates cells transfected with siRNA-
GPC3 and siRNA–TGF-β2; siRNA-G, cells transfected with siRNA-GPC3; siRNA-N, cells transfected with silencer negative control siRNA;
siRNA-T, cells transfected with siRNA–TGF-β2; V, vehicle control. Number of independent experiments = 3.
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Figure 7. Suppression of GPC3 in vivo delays tumor growth and upregulates cytoplasmic TGF-β2. (A, B) Orthotopic liver tumor models of
Huh7 and HepG2 cells stably expressing a trifusion reporter gene were given intraperitoneal injections of siRNA-GPC3 (25 nM), and
tumor growth was monitored weekly using the Xenogen IVIS 100 imaging system. Representative bioluminescence images of tumors
are shown at week 4 after siRNA treatment for HepG2 xenografts and at week 3 after siRNA treatment for Huh7 xenografts. *P < .05,
siRNA-N versus siRNA-GPC3 group. (C) Suppression of GPC3 in vivo also enhanced cytoplasmic TGF-β2 expression, reduced tumor
proliferation (reduced PCNA levels), and induced apoptosis (TUNEL assay) in both Huh7 and HepG2 xenografts. Representative images
are shown. Scale bar, 100 μm.
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for the first time that targeting GPC3 at the translational level in GPC3-
positive HCC cells activates TGF-β signaling, which, in turn, par-
tially mediates the antitumor effects of GPC3 suppression in HCC cells
in vitro and in vivo.
The TGF superfamily, including TGF-β, activin, and BMPs, modu-
lates many cellular responses, such as cell division, differentiation, and
cell fate decision [38]. Three different isoforms of TGF-β, TGF-β1,
TGF-β2, and TGF-β3, have similar but not identical biologic activities
[39]. TGF-β signaling is mediated through the binding of TGF-β with
TGF-β receptors (TGFBR), which, in turn, recruit and phosphorylate
downstream receptor–regulated SMADs (R-SMADs), SMAD2 or
SMAD3. Activation of R-SMADs may form signaling complexes with
SMAD4 and translocate to the nucleus eliciting tumor suppressive or
oncogenic effects [40]. Whereas TGF-β/SMAD signaling can be both
promoting and suppressing, its role in HCC progression is not com-
pletely understood [41]. Recently, TGF-β1 was reported to induce
cellular senescence and inhibit tumor growth in HCC cell lines by a
p53-independent and p21Cip1-dependent pathway [33].
Our results indicate that the antiproliferative effects of GPC3 in
HCC cells are partially mediated by TGF-β signaling. Suppression
of GPC3 in HCC cells overexpressing GPC3 inhibited cell prolifera-
tion associated with an increase in phosphorylation of SMAD2/3
and also arrested cell cycle progression at the G1 phase, associated with
down-regulation of cyclin A and cyclin D1, accumulation of p15Ink4b
and p21Cip1, and down-regulation of Rb phosphorylation. GPC3 sup-
pression also caused an accumulation of SA-β-Gal, an indicator of rep-
licative senescence. These cellular changes were recapitulated by the
addition of rhTGF-β2 to the HCC cells in culture, confirming the
involvement of TGF-β2 in cell cycle arrest and replicative senescence.
Moreover, the cotransfection of siRNAs against GPC3 and TGF-β2
partially reversed these effects on cell proliferation, cell cycle progres-
sion, replicative senescence, and the associated molecular changes. We
further observed an inverse correlation between the expression of GPC3
and TGF-β2, as GPC3 suppression upregulated TGF-β2 at both tran-
scriptional and translational levels. Thus, GPC3 may inversely regulate
TGF-β2, which, in turn, partially mediates the subsequent cellular and
molecular changes observed in HCC cells on GPC3 suppression.
The two HCC cell lines studied, HepG2 and Huh7, responded to
different extents toward GPC3 suppression, probably because of the
different genetic contexts between the two cell lines. The poorer re-
sponse of Huh7 cells may be explained by the following reasons. First,
Huh7 cells have shorter cell doubling time (24 hours) than HepG2
cells (33 h) and have a lower percentage of cells in the G1 phase
(56.39% ± 2.47%) than HepG2 cells (64.57% ± 2.84%) when cul-
tured in Dulbecco modified Eagle medium supplemented with 10%
FBS (P = .01). The shorter doubling time of Huh7 cells may allow the
cells to escape faster from the effect of transient siRNA knockdown.
Second, we observed that Wnt signaling was inactivated in HepG2
cells but not in Huh7 cells after GPC3 suppression (Figure W1, A-C).
Cooperatively, the regulation of Wnt and TGF-β signaling pathways
by GPC3 in HepG2 cells may lead to greater inhibitory effects on cell
growth and cell cycle progression in this cell line. Third, in Huh7 cells,
the ERK pathway might be the predominant pathway regulating prolif-
eration that is affected by GPC3 suppression (Figure W1D), and there-
fore, we observed a negligible effect of TGF-β2 siRNA on reversing cell
growth inhibition caused byGPC3 suppression. Fourth, Huh7 cells have
endogenous TGF-β2 expression but HepG2 cells do not. The endoge-
nous expression of TGF-β2 may mask the effect contributed by the low
and transient increase in TGF-β2 levels caused by GPC3 suppression.
In summary, we have shown that suppression of GPC3 activates
the TGF-β signaling pathway in HCC cells, eventually inhibiting cell
proliferation, arresting cell cycle progression at the G1 phase, and induc-
ing replicative senescence. The extent and biologic effects of GPC3
suppression vary, depending largely on the genetic context of the cells,
which reflects the heterogeneity of HCC tumors. Combined with pre-
vious reports that interference with GPC3 expression additionally regu-
lates at least two major signaling pathways (Wnt/β-catenin and ERK/
MAPK) in HCC, we suggest that interfering with GPC3 expression
and function exert broad-spectrum biologic effects that might be bene-
ficial for the treatment of the heterogeneous subtypes of HCC. Target-
ing GPC3 in HCC is widely applicable because it is overexpressed in
a large percentage (>60%) of HCC patients [4]. Further studies of the
mechanisms by which GPC3 regulates multiple signaling pathways
may reveal other points of intervention for this important target.
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Figure W1. Effects of GPC3 suppression on the Wnt and ERK/MAPK signaling pathways in Huh7 and HepG2. (A) Suppression of GPC3
by siRNA-GPC3 did not affect the expression of total β-catenin in both Huh7 and HepG2 but inhibited the nuclear localization of β-catenin
in HepG2 cells only as shown by Western blot analysis (B) and immunofluorescence (C). (D) Suppression of GPC3 by siRNA-GPC3
reduced phosphorylation of ERK1/2 in Huh7 cells but not in HepG2 cells. siRNA-G indicates cells transfected with siRNA-GPC3; siRNA-N,
cells transfected with siRNA-N; V, vehicle control. Histone H3 was used as the loading control for nuclear proteins. Number of independent
experiments = 3.
